Literature DB >> 17951290

Global sequencing approach for characterizing the molecular background of hereditary iron disorders.

Séverine Cunat1, Muriel Giansily-Blaizot, Michael Bismuth, François Blanc, Olivier Dereure, Dominique Larrey, Alain Le Quellec, Philippe Pouderoux, Christian Rose, Isabelle Raingeard, Eric Renard, Jean-François Schved, Patricia Aguilar-Martinez.   

Abstract

BACKGROUND: New genetic forms of hereditary hemochromatosis (HH) or hereditary hyperferritinemia (HF) have been identified over the last few years, and abnormalities of various genes may interact in a single patient. This study aimed to develop a rapid automated method for sequencing the main genes involved.
METHODS: We used a standard 96-well microplate with a single PCR condition in an adaptation of the SCAIP (single-condition amplification with internal primer) method to sequence the HFE (hemochromatosis), HAMP (hepcidin antimicrobial peptide), HFE2/HJV [hemochromatosis type 2 (juvenile)], SLC40A1 (ferroportin), and TFR2 (transferrin receptor 2) genes, and the 5' untranslated region of the FTL (ferritin, light polypeptide) gene. To further simplify the method, we adjusted PCR conditions to avoid the use of an internal primer and applied this single-condition amplification method to 38 selected, unrelated patients. We tailored the genetic investigation according to the clinical picture, with the patients falling into 2 groups. Group 1 consisted of patients with hyperferritinemia and high transferrin saturation (TS) (classic adult and juvenile HH forms, groups 1A and 1B, respectively), and group 2 consisted of patients with hyperferritinemia and low, typical, or slightly increased TS, with or without iron overload (groups 2A and 2B, respectively).
RESULTS: With this strategy we identified single-gene and multigene abnormalities, including 6 previously undescribed abnormalities in HFE (c.794dupA), HFE2 (c.-89-4dupT), and SLC40A1 (c.262A>G, c.533G>A, c.1468G>A, and c.-59_-45del).
CONCLUSION: This method is a simple approach for investigating hereditary iron overload or HF and allows rapid evaluation of patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17951290     DOI: 10.1373/clinchem.2007.090605

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  12 in total

1.  Iron overload in HFE C282Y heterozygotes at first genetic testing: a strategy for identifying rare HFE variants.

Authors:  Patricia Aguilar-Martinez; Bernard Grandchamp; Séverine Cunat; Estelle Cadet; François Blanc; Marlène Nourrit; Kaiss Lassoued; Jean-François Schved; Jacques Rochette
Journal:  Haematologica       Date:  2011-01-12       Impact factor: 9.941

Review 2.  Hepcidin and ferroportin: the new players in iron metabolism.

Authors:  Ivana De Domenico; Diane McVey Ward; Jerry Kaplan
Journal:  Semin Liver Dis       Date:  2011-09-07       Impact factor: 6.115

Review 3.  Physiology of iron metabolism.

Authors:  Sophie Waldvogel-Abramowski; Gérard Waeber; Christoph Gassner; Andreas Buser; Beat M Frey; Bernard Favrat; Jean-Daniel Tissot
Journal:  Transfus Med Hemother       Date:  2014-05-12       Impact factor: 3.747

4.  Ferroportin disease: a systematic meta-analysis of clinical and molecular findings.

Authors:  Roman Mayr; Andreas R Janecke; Melanie Schranz; William J H Griffiths; Wolfgang Vogel; Antonello Pietrangelo; Heinz Zoller
Journal:  J Hepatol       Date:  2010-07-17       Impact factor: 25.083

5.  Reduced iron export associated with hepcidin resistance can explain the iron overload spectrum in ferroportin disease.

Authors:  André Viveiros; Marlene Panzer; Nadja Baumgartner; Benedikt Schaefer; Armin Finkenstedt; Benjamin Henninger; Igor Theurl; Karin Nachbaur; Günter Weiss; Roland Haubner; Clemens Decristoforo; Herbert Tilg; Heinz Zoller
Journal:  Liver Int       Date:  2020-06-12       Impact factor: 5.828

6.  The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of next-generation sequencing data.

Authors:  Daniel F Wallace; V Nathan Subramaniam
Journal:  Genet Med       Date:  2015-12-03       Impact factor: 8.822

7.  Functional characterization of a novel SLC40A1 Arg88Ile mutation in a kindred with familial iron overload treated by phlebotomy.

Authors:  Jihad Womack; Abitha Sukumaran; Xiuqi Li; Larisa Lozovatsky; Patrick G Gallagher; Jerome E Seid; Karin E Finberg
Journal:  Blood Cells Mol Dis       Date:  2020-12-24       Impact factor: 3.039

8.  Ferroportin disease mutations influence manganese accumulation and cytotoxicity.

Authors:  Eun-Kyung Choi; Trang-Tiffany Nguyen; Shigeki Iwase; Young Ah Seo
Journal:  FASEB J       Date:  2018-09-24       Impact factor: 5.834

Review 9.  Ferroportin disease: pathogenesis, diagnosis and treatment.

Authors:  Antonello Pietrangelo
Journal:  Haematologica       Date:  2017-11-03       Impact factor: 9.941

10.  The SLC40A1 R178Q mutation is a recurrent cause of hemochromatosis and is associated with a novel pathogenic mechanism.

Authors:  Chandran Ka; Julie Guellec; Xavier Pepermans; Caroline Kannengiesser; Cécile Ged; Wim Wuyts; David Cassiman; Victor de Ledinghen; Bruno Varet; Caroline de Kerguenec; Claire Oudin; Isabelle Gourlaouen; Thibaud Lefebvre; Claude Férec; Isabelle Callebaut; Gérald Le Gac
Journal:  Haematologica       Date:  2018-07-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.